Abemaciclib and Letrozole in Treating Patients With Endometrial Cancer
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This early phase I trial studies how well abemaciclib and letrozole work in treating patients
with endometrial cancer and determines whether there are changes in patients' cancer cell
biomarkers (a genetic feature or specific protein) for cell growth before and after
treatment. Antihormone therapy with aromatase inhibitors, such as letrozole, may lessen the
amount of estrogen made by the body. Abemaciclib blocks the activities of a class of proteins
called cyclin-dependent kinase, which are involved in cell duplication. Giving letrozole and
abemaciclib together may slow down cancer cell growth in patients with endometrial cancer.